ProKidney Corp. (PROK) 10-Year Financial Performance & Capital Metrics

PROK • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.Show more

Revenue $76K
EBITDA -$178M -20.7%
Net Income -$61M -72.5%
EPS (Diluted) -0.62 -8.8%
Gross Margin 100%
EBITDA Margin -234531.58%
Operating Margin -241678.95%
Net Margin -80507.89%
ROE -15.43% -95.0%
ROIC -42.99% +33.4%
Debt/Equity 0.01 -28.6%
Interest Coverage -20408.44 -61.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 82 (top 18%)
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 58.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-55.74%

EPS CAGR

10Y-

5Y-

3Y-

TTM0.94%

ROCE

10Y Avg-180.04%

5Y Avg-122.07%

3Y Avg-45.55%

Latest-45.9%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	76K
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	76K
Gross Margin %	-	-	-	-	-	1%
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	79.38M	27.02M	55.11M	153.01M	151.52M	183.75M
OpEx % of Revenue	-	-	-	-	-	2417.79%
Selling, General & Admin	4.16M	5.98M	8.86M	70.94M	44.81M	56.08M
SG&A % of Revenue	-	-	-	-	-	737.95%
Research & Development	75.22M	21.04M	46.26M	82.07M	106.71M	127.67M
R&D % of Revenue	-	-	-	-	-	1679.84%
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-79.38M	-27.02M	-55.11M	-153.01M	-151.52M	-183.68M
Operating Margin %	-	-	-	-	-	-2416.79%
Operating Income Growth %	-	0.66%	-1.04%	-1.78%	0.01%	-0.21%
EBITDA+	-78.51M	-26.06M	-53.13M	-149.97M	-147.67M	-178.24M
EBITDA Margin %	-	-	-	-	-	-2345.32%
EBITDA Growth %	-	0.67%	-1.04%	-1.82%	0.02%	-0.21%
D&A (Non-Cash Add-back)	867K	964K	1.98M	3.04M	3.85M	5.43M
EBIT	-19.16M	-27.02M	-55.11M	-147.02M	-129.44M	-163.92M
Net Interest Income+	126	43K	2K	5.77M	22.07M	19.74M
Interest Income	126	43K	2K	5.98M	22.08M	19.75M
Interest Expense	0	0	0	215K	12K	9K
Other Income/Expense	126K	43K	2K	5.77M	22.07M	19.74M
Pretax Income+	-79.25M	-26.98M	-55.11M	-147.24M	-129.45M	-163.93M
Pretax Margin %	-	-	-	-	-	-2157.01%
Income Tax+	361K	-232K	38K	896K	6M	-598K
Effective Tax Rate %	1%	0.99%	1%	0.73%	0.27%	0.37%
Net Income+	-79.61M	-26.75M	-55.15M	-108.03M	-35.47M	-61.19M
Net Margin %	-	-	-	-	-	-805.08%
Net Income Growth %	-	0.66%	-1.06%	-0.96%	0.67%	-0.73%
Net Income (Continuing)	-79.61M	-26.75M	-55.15M	-148.13M	-135.45M	-163.34M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	1.6B	1.49B	1.4B
EPS (Diluted)+	-1.01	-0.14	-1.73	-1.76	-0.57	-0.62
EPS Growth %	-	0.86%	-11.36%	-0.02%	0.68%	-0.09%
EPS (Basic)	-1.01	-0.14	-1.73	-1.76	-0.57	-0.62
Diluted Shares Outstanding	78.53M	186.5M	31.89M	61.54M	61.71M	97.92M
Basic Shares Outstanding	78.53M	186.5M	31.89M	61.54M	61.71M	97.92M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	15.42M	5.58M	27.27M	504.72M	374.15M	395.88M
Cash & Short-Term Investments	15.23M	4.58M	20.56M	490.25M	362.95M	358.29M
Cash Only	15.23M	4.58M	20.56M	490.25M	60.65M	99.12M
Short-Term Investments	0	0	0	0	302.3M	259.17M
Accounts Receivable	0	0	0	0	1.38M	2.45M
Days Sales Outstanding	-	-	-	-	-	11.75K
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	52K	25K	1.38M	9K	19.45M
Total Non-Current Assets+	4.18M	11.12M	13.03M	13.28M	46.41M	45.19M
Property, Plant & Equipment	3.33M	10.47M	12.6M	13.06M	46.41M	45.19M
Fixed Asset Turnover	-	-	-	-	-	0.00x
Goodwill	0	641.36K	0	0	0	0
Intangible Assets	857K	642	428K	213K	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0
Total Assets+	19.61M	16.7M	40.3M	518M	420.55M	441.07M
Asset Turnover	-	-	-	-	-	0.00x
Asset Growth %	-	-0.15%	1.41%	11.85%	-0.19%	0.05%
Total Current Liabilities+	2.71M	5.5M	12.31M	10.87M	25.04M	36.22M
Accounts Payable	480K	781K	2.83M	3.04M	5.1M	3.63M
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	355K	1.71M	0	0	7.52M	11.45M
Current Ratio	5.68x	1.02x	2.21x	46.42x	14.94x	10.93x
Quick Ratio	5.68x	1.02x	2.21x	46.42x	14.94x	10.93x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	1.01M	1.33M	1.07M	2.18M	4.18M	3.22M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	1.01M	1.33M	1.07M	1.91M	3.61M	2.47M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	278K	568K	748K
Total Liabilities	3.72M	6.84M	13.38M	13.06M	29.22M	39.44M
Total Debt+	1.11M	1.56M	1.33M	2.4M	4.41M	3.24M
Net Debt	-14.11M	-3.02M	-19.22M	-487.85M	-56.24M	-95.88M
Debt / Equity	0.07x	0.16x	0.05x	0.00x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-711.66x	-12626.83x	-20408.44x
Total Equity+	15.88M	9.86M	26.92M	504.94M	391.34M	401.64M
Equity Growth %	-	-0.38%	1.73%	17.76%	-0.22%	0.03%
Book Value per Share	0.20	0.05	0.84	8.21	6.34	4.10
Total Shareholders' Equity	15.88M	9.86M	26.92M	-1.1B	-1.1B	-994.95M
Common Stock	95.5M	116.23M	188.43M	24K	23K	29K
Retained Earnings	-79.61M	-106.36M	-161.51M	-1.1B	-1.14B	-1.2B
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	130K	130K
Minority Interest	0	0	0	1.6B	1.49B	1.4B

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-76.81K	-25.18M	-50.3M	-77.09M	-90.07M	-126.35M
Operating CF Margin %	-	-	-	-	-	-1662.51%
Operating CF Growth %	-	-326.85%	-1%	-0.53%	-0.17%	-0.4%
Net Income	-79.61K	-26.75M	-55.15M	-148.13M	-135.45M	-163.34M
Depreciation & Amortization	867	964K	1.98M	3.04M	3.85M	5.43M
Stock-Based Compensation	498	730K	699K	74.47M	30.85M	29.37M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	1.56K	0	0	0	-6M	-1.78M
Working Capital Changes	-115	-126K	2.16M	-6.46M	16.67M	3.96M
Change in Receivables	0	0	0	0	-1.38M	-1.07M
Change in Inventory	0	0	0	0	0	0
Change in Payables	0	683K	5K	494K	11.64M	11.59M
Cash from Investing+	-2.97K	-5.46M	-5.19M	-1.74M	-329.98M	20.41M
Capital Expenditures	-1.3K	-5.46M	-5.19M	-1.85M	-34.2M	-29.51M
CapEx % of Revenue	-	-	-	-	-	388.28%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	20K	19.99M	71.47M	548.52M	-9.55M	144.41M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	20K	20M	0	542.5M	0	140K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-78.11K	-30.64M	-55.49M	-78.94M	-124.27M	-155.86M
FCF Margin %	-	-	-	-	-	-2050.79%
FCF Growth %	-	-391.22%	-0.81%	-0.42%	-0.57%	-0.25%
FCF per Share	-0.00	-0.16	-1.74	-1.28	-2.01	-1.59
FCF Conversion (FCF/Net Income)	0.00x	0.94x	0.91x	0.71x	2.54x	2.07x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	145K	68K	1.95M	2.86M	73K

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-501.26%	-207.78%	-299.86%	-40.62%	-7.91%	-15.43%
Return on Invested Capital (ROIC)	-3365.46%	-470.58%	-568.61%	-926.23%	-64.53%	-42.99%
Gross Margin	-	-	-	-	-	100%
Net Margin	-	-	-	-	-	-80507.89%
Debt / Equity	0.07x	0.16x	0.05x	0.00x	0.01x	0.01x
Interest Coverage	-	-	-	-711.66x	-12626.83x	-20408.44x
FCF Conversion	0.00x	0.94x	0.91x	0.71x	2.54x	2.07x

Frequently Asked Questions

Growth & Financials

ProKidney Corp. (PROK) reported $0.7M in revenue for fiscal year 2024.

ProKidney Corp. (PROK) grew revenue by 0.0% over the past year. Growth has been modest.

ProKidney Corp. (PROK) reported a net loss of $71.0M for fiscal year 2024.

Dividend & Returns

ProKidney Corp. (PROK) has a return on equity (ROE) of -15.4%. Negative ROE indicates the company is unprofitable.

ProKidney Corp. (PROK) had negative free cash flow of $146.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener